Dansk aktör köper krisande amerikanskt cancerbolag

Danska Pharmacosmos tar över det amerikanska läkemedelsbolaget G1 Therapeutics i en affär som uppgår till 405 miljoner dollar.

Come see us at the upcoming events!

We have some upcoming events where you can see our latest products live!

Anna Törner: Yes, I Am Sick, But Not Weak

”People often say that someone who is ill only has one wish—to get better. But I think that is not true. Someone who is ill also longs to be understood, to be r...

The investor: “The major common diseases are hot again”

She has previously been voted Investor of the Year and will now be moderating The Future of Swedish & Danish Life Science congress. We check the temperature of ...

"Unclear proposal from the EU Commission on how to solve the MDR challenges"

Even before the EU regulation on medical devices (MDR) came into force, medical technology companies and doctors were concerned that it would endanger the avail...

Achieve Efficient, Fast Targeting of Your Sample

Step into the future of imaging technology with VersaXRM 730.

Why the world renown researcher Marc Tessier-Lavigne resigns as Stanford´s president

In mid-summer, neuroscientist Marc Tessier-Lavigne announced his resignation as President of Stanford following allegations of manipulated study data. According...

Are you ready for EMC 2024?

Visit ZEISS at Europe’s largest Event dedicated to Microscopy and Imaging.

Ny mpox-variant sprids från Kongo – ökad efterfrågan på vaccin

En dödligare variant av mpox sprids från Demokratiska Republiken Kongo och utgör en risk för barn. Viruset orsakar feber, huvudvärk, muskelvärk, smärtsamma böld...

Tio life science-projekt får miljonanslag – ny utlysning öppnar

En rad life science-projekt har fått miljonanslag i ett svenskt proof of concept-program. 13 januari öppnar en ny utlysning.

Optimize Your Visibility

ZEISS presents our newest VersaXRM® 730 3D X-ray microscope.

Italian pharmaceutical company buys rights to immunotherapy from Sanofi

Italy's Recordati buys the rights to a treatment for the rare autoimmune disease cold agglutinin disease (CAD).

Inget statligt stöd för fetmaläkemedel – aktien för läkemedelsjättar pressas

Trump-administrationen slopar Bidens förslag om att om att inkludera fetmaläkemedel i sjukförsäkringen Medicare. Det innebär ett bakslag för Novo Nordisk och El...

Claims of life science companies fleeing abroad is a myth according to survey

The claim that life science companies are moving abroad is exaggerated. In fact, only a tiny percentage is leaving the country, according to a survey.

Thumbs down for lecanemab in the EU – “Very surprised”

The Azheimer's drug lecanemab has received a negative assessment from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), acc...

Healthcare study: Alzheimer’s blood test shows high accuracy

A blood test for identifying Alzheimer’s has now been tested in the general healthcare setting. According to the researchers, the test was 90% accurate in making a diagnosis.

A small thing that can solve your problems

If you are in need of a compact valve. Look no further! We have the VOVK

Pharmaevent lockade internationella deltagare

Under tisdagen arrangerade Life Science Sweden eventet Pharma Outsourcing. I år var deltagare från över 10 länder på plats i Life City i Hagastaden.

TFS Trial Form Support AB

MSD discontinues two Keytruda trials

MSD has stopped two late-stage trials that tested its blockbuster immunotherapy Keytruda as a treatment for skin and lung cancer.

Amrop Malmö AB

Stark uppgång för Crispr-behandlingar

Behandlingar som använder gensaxen Crispr växer fram som en av de hetaste medicinska trenderna i USA – och läkemedelsmyndigheten FDA gör sitt bästa för att stöd...

Bioscience – Groundbreaking Research & Diagnostics: Stockholm (2026)

Swedish pavilion with healthcare companies at Ukraine fair – “Ukraine is being rebuilt right now”

Private companies and public authorities are both needed in the reconstruction of Ukraine, said Minister for Health Care, Acko Ankarberg Johansson, in her openi...